Efficacy of golimumab in patients with refractory non-infectious panuveitis
1
Issued Date
2024-12-01
Resource Type
eISSN
20452322
Scopus ID
2-s2.0-85183055627
Pubmed ID
38273077
Journal Title
Scientific Reports
Volume
14
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Scientific Reports Vol.14 No.1 (2024)
Suggested Citation
Tungsattayathitthan U., Tesavibul N., Choopong P., Treeratsakulchai C., Ngathaweesuk Y., Sanphan W., Boonsopon S. Efficacy of golimumab in patients with refractory non-infectious panuveitis. Scientific Reports Vol.14 No.1 (2024). doi:10.1038/s41598-024-52526-1 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/95593
Title
Efficacy of golimumab in patients with refractory non-infectious panuveitis
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
This study investigated the efficacy of golimumab in the management of refractory non-infectious panuveitis. Nineteen patients (38 eyes; mean age, 31 years) were retrospectively reviewed between June 2016 and June 2022. All patients had bilateral eye involvement and Behçet’s disease was the most common diagnosis (57.9%). Compared to the period before golimumab treatment, the rate of uveitis relapses after golimumab treatment significantly decreased from 1.73 to 0.62 events per person-years (incidence ratio 0.33, 95% confidence interval 0.19–0.57, P < 0.001). After golimumab therapy, 12 patients (63.2%) were able to reduce the number or dosage of immunosuppressive drugs, and the median dosage of systemic corticosteroids was reduced from 15.0 to 7.5 mg/d (P = 0.013) compared to baseline. The median logMAR visual acuity improved from 0.9 at baseline to 0.6 at the last visit (P = 0.006). Golimumab demonstrated efficacy against refractory non-infectious panuveitis in terms of a corticosteroid-sparing effect and reduced the rate of uveitis relapses to approximately one-third.